VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has appointed Raju Willener as chief financial officer, effective immediately. Willener brings more than three decades of international financial leadership experience, including roles in global capital markets, investment banking, corporate finance, asset management, and strategic leadership. He will report to CEO and Co-Founder Christoph Antz, Ph.D., and is expected to support the company's capital strategy, strategic opportunities, and continued development of its proprietary BiTAC(R) technology platform and oncology pipeline.
Willener's appointment comes at a pivotal time for VERAXA as it advances its pipeline of bispecific T cell engagers and antibody-drug conjugates (ADCs) toward clinical development. His extensive background in corporate finance and capital markets is likely to be instrumental in securing the funding necessary to drive these programs forward. "We are delighted to welcome Raju to VERAXA," said Christoph Antz. "His deep expertise in financial strategy and capital markets will be invaluable as we continue to scale our operations and advance our innovative BiTAC platform."
Prior to joining VERAXA, Willener served as director of corporate development at Exentis Group AG before being appointed CFO in 2025, where he led M&A initiatives, financial strategy, and key corporate functions. Earlier in his career, he held senior executive and investment positions overseeing corporate finance, capital markets, investor relations, and investment portfolios exceeding CHF 30 billion in assets under management. His track record of leadership in both public and private companies positions him well to guide VERAXA's financial strategy during a period of significant growth and scientific advancement.
The BiTAC platform, developed from breakthroughs at the European Molecular Biology Laboratory (EMBL), represents a novel approach to cancer therapy by engineering bispecific antibodies that can engage T cells to target and eliminate tumor cells. VERAXA is also exploring bispecific ADCs and other innovative formats, aiming to address significant unmet needs in oncology. The company's commitment to rigorous quality-by-design principles underscores its focus on developing safe and effective therapeutics.
Willener's appointment is expected to enhance VERAXA's ability to navigate the complex financial landscape of the biotech industry. With his leadership, the company is better positioned to pursue strategic partnerships, manage capital resources, and potentially attract additional investment to fuel its research and development efforts. As VERAXA continues to progress its pipeline, the addition of a seasoned financial executive like Willener signals a strategic move to strengthen its corporate infrastructure and maximize shareholder value.
Investors and industry observers will be watching closely to see how Willener's expertise influences VERAXA's next steps. The company's focus on next-generation antibody-based therapies places it at the forefront of cancer research, and the financial acumen Willener brings could be key to translating scientific innovation into clinical success. For more information on VERAXA Biotech and its pipeline, visit https://nnw.fm/jcHOU.
